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low HDL-cholesterol obese phenotype
independently of insulin resistance and CRP level
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Audrey Bégu-Le Corroller5, Noémie Dubois5, Rachel Grangeot5, Catherine Mattei5, Jean Gaudart6, Alain Nicolay1,3,
Henri Portugal1,3, Bernard Vialettes1,5 and René Valéro1,5,7*
Abstract
Background: Low plasma high-density lipoprotein-cholesterol (HDL-c) level is commonly present in obesity and
represents an independent cardiovascular risk factor. However, obese patients are a very heterogeneous population
and the factors and mechanisms that contribute to low HDL-c remain unclear. The aim of this study was to
investigate the association between plasma HDL-c levels and plasma hormonal profiles (insulin, adiponectin,
resistin, leptin and ghrelin) in subsets of class II and III obese patients.
Methods: Fasting plasma levels of glucose, total cholesterol, LDL-c, HDL-c, triglycerides, free fatty acids, apoproteins
A-I, B-100, B-48, C-II, C-III, insulin, hs-CRP, adipocytokines (adiponectin, resistin, leptin), unacylated ghrelin, body
composition (DXA) and resting energy expenditure were measured in three subsets of obese patients: 17
metabolically abnormal obese (MAO) with metabolic syndrome and the typical metabolic dyslipidaemia, 21
metabolically healthy obese (MHO) without metabolic syndrome and with a normal lipid profile, and 21 isolated
low HDL-c obese patients (LHO) without metabolic syndrome, compared to 21 healthy lean control subjects.
Results: Insulin resistance (HOMA-IR) increased gradually from MHO to LHO and from LHO to MAO patients (p <
0.05 between MHO and MAO and between LHO and MAO). In multiple regression analysis, serum unacylated
ghrelin levels were only positively and independently associated with HDL-c levels in the LHO group (p = 0.032).
Conclusions: These results suggest that, in class II and III obese patients with an isolated low HDL-c phenotype,
unacylated ghrelin is positively associated with HDL-c level independently of insulin resistance and CRP levels, and
may contribute to the highly prevalent low HDL-c level seen in obesity.
Keywords: Adiponectin, Apolipoprotein, Cardiovascular risk, Ghrelin, HDL-cholesterol, Inflammation, Insulin resis-
tance, Lipids, Obesity
Background
Obesity is becoming a global epidemic, and the preva-
lence of class II and III obesity is constantly increasing.
Insulin resistance is common in obese patients and is a
cornerstone in the pathophysiology of metabolic syn-
drome [1]. Cardiovascular diseases are the primary
cause of morbidity and mortality in obesity. Each 5 kg/
m2 increase above a body mass index (BMI) of 25 kg/
m2 results in a 40% increase in cardiovascular mortality
[2]. A dyslipidaemia is often present and represents a
major cardiovascular risk factor. This typical dyslipidae-
mia is characterised by the quartet: hypertriglyceridae-
mia, reduction in HDL-cholesterol (HDL-c), increased
small and dense low-density lipoproteins (LDL) and
post-prandial hyperlipidaemia [3]. A number of studies
have shown that low plasma HDL-c levels are an inde-
pendent cardiovascular risk factor [4].
However, obese patients are a very heterogeneous
population. For instance, the new concept of a metaboli-
cally healthy obese (MHO) group has emerged [5]. This
subset of obese individuals, who could represent up to
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30% of the obese population [6], is characterised by high
insulin sensitivity, no sign of hypertension, normal lipid,
inflammation and hormonal profiles and a low incidence
of cardiovascular diseases [5]. Although still discussed,
visceral adiposity appears to be more closely linked to
insulin resistance, atherogenic dyslipidaemia, decreased
blood adiponectin level and inflammation than subcuta-
neous adiposity [7,8]. Nevertheless, the criteria used to
distinguish between MHO and at-risk obese individuals
are poorly defined and the factors and mechanisms that
could explain these different metabolic profiles, particu-
larly HDL-c level, remain unclear.
Adipocytokines secreted by adipose tissue, such as adi-
ponectin, leptin and resistin, play major roles in the reg-
ulation of energy metabolism and/or insulin sensitivity
[9,10] and could directly or indirectly modulate lipid
metabolism [11]. Likewise, the ghrelin hormone, pro-
duced predominantly by the stomach, is involved in
energy balance regulation, insulin sensitivity and adipos-
ity [12,13]. However, no study has yet investigated the
link between HDL-c level and hormonal profiles in dif-
ferent subsets of obese patients.
In the present study, our main objective was to inves-
tigate the potential link between HDL-c levels and hor-
monal profiles (insulin, adipocytokines, ghrelin) in
different subsets of obese patients: 1) the metabolically
abnormal obese (MAO) with metabolic syndrome and
the typical metabolic dyslipidaemia; 2) the metabolically
healthy obese (MHO) with no metabolic syndrome and
with a normal lipid profile; and 3) the low HDL-c obese
(LHO) with no metabolic syndrome but with an isolated
low HDL-c level; in comparison to 4) healthy and lean
control subjects.
Methods
Subjects
This study was conducted in accordance with the
Declaration of Helsinki, approved by the institutional
ethics committee, and written informed consent was
obtained from all patients. We recruited the obese
patients from among those who were referred to our
nutrition department with an indication for bariatric
surgery (class II and III obesity). All obese patients and
21 lean normolipidaemic control subjects (5 males, 16
females; mean age: 33 ± 6 years (yr); mean BMI: 22.1 ±
2.9 kg/m2; waist circumference: 74.8 ± 7.6 cm) under-
went a physical examination and laboratory tests to
ensure they had no exclusion criteria. The patients were
eligible if they did not smoke and drink less than 20 g
alcohol/day, if they had normal fasting blood glucose (<
6.1 mmol/L), normal blood pressure (systolic blood
pressure < 140 mmHg and diastolic blood pressure < 90
mmHg), no hepatic, renal, thyroid or haematological
abnormalities, no inflammatory disease, and had not
been treated with a drug that could interfere with insu-
lin sensitivity or lipid metabolism. We included 59
obese patients who were divided into three groups: a
first group of 17 obese patients with metabolic syn-
drome according to the National Cholesterol Education
Program’s Adult treatment panel III report [14] and
determined by the presence of the three following cri-
teria: central obesity (waist circumference > 102 cm for
males and > 88 cm for females), hypertriglyceridaemia
(triglycerides: ≥ 1.7 mmol/L) and low HDL-c (< 1
mmol/L for males and < 1.3 mmol/L for females)
(MAO group) (6 males, 11 females; mean age: 38 ± 11
yr; mean BMI: 43.3 ± 4.7 kg/m2; waist circumference:
129.0 ± 14.3 cm); a second group of 21 obese patients
with no metabolic syndrome and with normal HDL-c
level (> 1 mmol/L for males and females) (MHO group)
(4 males, 17 females; mean age: 37 ± 5 yr; mean BMI:
41.4 ± 4.1 kg/m2; waist circumference: 121.1 ± 13.5 cm);
a third group of 21 obese patients with no metabolic
syndrome but with an isolated low HDL-c level (< 1
mmol/L for males and females) (LHO group) (6 males,
15 females; mean age: 34 ± 9 yr; mean BMI: 48.4 ± 8.3
kg/m2; waist circumference: 137.0 ± 15.4 cm).
Laboratory methods
Blood samples were collected from each subject the morn-
ing after an overnight fast. Plasma was separated from ery-
throcytes by centrifugation (15 min, 3500 rpm, 4°C).
Plasma glucose was measured using the hexokinase
oxidase method (Beckman Coulter, Galway, Ireland) and
plasma insulin levels were assessed using the electroche-
miluminescence method (Roche Diagnostic, Mannhein,
Germany). Insulin resistance was estimated using the
homeostasis model assessment: HOMA-IR = fasting
insulin (mUI/L) × fasting glucose (mmol/L)/22.5.
Plasma total cholesterol, HDL-c, LDL-c and triglycer-
ides were determined using enzymatic methods
(CHOD-PAP, HDL-c plus and GPOPAP, respectively,
Roche, Grenoble, France). Free fatty acids (FFA) were
determined using a colorimetric method (Wako Indus-
trials, Osaka, Japan).
Plasma high-sensitivity C-reactive protein (hs-CRP)
was measured using the turbidimetric method (Syn-
chron LX®, Beckman Coulter, Paris, France).
Serum concentrations of ApoC-II and ApoC-III were
determined by an immunoturbidimetric assay using K-
ASSAY kits (Kamiya Biomedical Company, Seattle, WA,
USA). Serum concentrations of ApoA-I and ApoB-100
were determined by an immunonephelometry assay
(Dade Behring Company, Marburg, Germany). Plasma
concentrations of ApoB-48 were measured using an
ELISA kit (Shibayagi, Gunma, Japan).
Specific ELISA kits were used to measure serum levels
of leptin (Active Human Leptin, DSL Systems, Webster,
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TX, USA), adiponectin (Quantikine Human Adiponec-
tin, R&D Systems, Minneapolis, MN, USA), resistin
(Quantikine Human Resistin, R&D Systems, Minneapo-
lis, MN, USA) and ghrelin (Human Unacylated Ghrelin,
Biovendor, Montigny, France).
Body composition was assessed by dual energy X-ray
absorptiometry (DXA) method (Lunar iDXA and
enCORE software version 2007, GE Healthcare, Chalfont
St Giles, United Kingdom): body fat mass (BFM) and fat
free mass (FFM) compartments were considered. Resting
energy expenditure (REE) was measured by indirect
calorimetry (Quark-RMR-Cosmed, Rome, Italy).
Statistical analyses
Statistical analyses were performed using SPSS (Statisti-
cal Package for the Social Sciences, version 15.0, Chi-
cago, IL, USA) software. The results are presented as
means ± SD. The Mann-Whitney U-test was used for
comparisons between groups. Before the analyses, the
variables with skewed distributions were logarithmically
transformed to normalize their distributions. Correla-
tions were evaluated by linear regression and multiple
interactions by stepwise regression and by exhaustive
checks of all possible multivariate models. Variables
with univariate correlation with a p < 0.05 were
included in the multivariate regression. The structure of
the covariance matrix for each variable was taken into
account in all analyses to ensure the most adequate sta-
tistical fit and power. A p-value < 0.05 was considered
statistically significant.
Results
The anthropometric, body composition, biochemical and
hormonal characteristics of the three groups of obese
patients and the control group are presented in Table 1.
There was no difference in age or gender ratio between
the obese groups and the control group.
Comparisons between the three obese groups and
control subjects
As expected, the three obese groups were bigger, had
increased waist circumferences, were more insulin resis-
tant and had higher hs-CRP levels than control subjects
(p < 0.05 for all parameters). The lipid and apoprotein
profiles did not differ between the MHO group and the
control group. The MAO group and the LHO groups
both had decreased plasma HDL-c and apoprotein A-I
levels and increased FFA levels compared to the control
group (p < 0.05 for all parameters). Only the MAO
group with metabolic syndrome showed higher plasma
triglycerides and higher levels of apoproteins B-100, B-
48, C-II and C-III than the control group (p < 0.05 for
all parameters). The hormonal profile showed higher
serum leptin and resistin levels and lower serum ghrelin
levels in the three obese groups compared to the control
group (p < 0.05 for all parameters), but decreased serum
adiponectin levels was only observed in the MAO (p <
0.05) and LHO groups (p < 0.05) (Table 1).
Comparisons between MHO and MAO groups
There were no differences in the body composition and
the REE between MHO and MAO patients (Table 1).
The lipid profiles showed higher plasma triglycerides,
apoproteins B-100, B-48, C-II and C-III and lower
HDL-c and apoprotein A-I levels in the MAO group (p
< 0.05 for all parameters) (Table 1).
The hormonal profile showed higher insulin resistance
and lower serum adiponectin levels in the MAO group
(p < 0.05 for all parameters). However, there was no dif-
ference in the levels of serum leptin, resistin and ghrelin
(Table 1).
Comparisons between MHO and LHO groups
The LHO group had a higher BMI than that of MHO
patients (p < 0.05), but there were no differences in the
body composition and REE between the two groups
(Table 1).
The lipid profile showed lower HDL-c and apoprotein
A-I levels and higher FFA and hs-CRP levels in the
LHO patients (p < 0.05 for all parameters) (Table 1).
The hormonal profile showed higher serum leptin
levels in the LHO group (p < 0.05), but there were no
difference in insulin resistance or serum adiponectin,
resistin or ghrelin levels (Table 1).
Comparisons between MAO and LHO groups
There were no differences in the body composition and
REE between the MAO and LHO groups (Table 1).
The lipid profile showed higher plasma triglycerides,
apoproteins B-100, B-48, C-II and C-III levels in the
MAO group (p < 0.05 for all parameters). Hs-CRP levels
were higher in the LHO group (p < 0.05) (Table 1).
The hormonal profile showed higher insulin resistance
and lower serum leptin levels in the MAO group (p <
0.05 for all parameters), but no difference in the serum
adiponectin, resistin or ghrelin levels (Table 1).
Stepwise multivariate analysis
To assess the relationships between HDL-c or triglycer-
ides and several variables, a stepwise multivariate analy-
sis was carried out and adjusted for age, gender, BMI,
waist, BFM, FFM, glucose, HOMA-IR, hs-CRP, FFA,
apoB-100, apoB-48, apoC-II, apoC-III, apoC-III/apoC-II,
insulin, adiponectin, leptin, resistin, and ghrelin for all
three groups of obese patients and the non obese con-
trol group (Table 2). The analysis showed that, in the
control group, insulin was associated negatively and sig-
nificantly (b = -0.423; p = 0.039) with the variability of
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HDL-c and explained 35% of the plasma HDL-c var-
iance (r2 = 0.35) (Figure 1A). In addition, adiponectin
was associated negatively and significantly (b = -0.384; p
= 0.041) with the variability of triglycerides and
explained 22% of the plasma triglycerides variance (r2 =
0.22). In the MHO group, BMI was associated negatively
and significantly (b = -0.732; p = 0.028) with the varia-
bility of HDL-c and explained 32% of the plasma HDL-c
variance (r2 = 0.32) (Figure 1B). In addition, adiponectin
was associated negatively and significantly (b = -0.414; p
= 0.037) with the variability of triglycerides and
explained 29% of the plasma triglycerides variance (r2 =
0.29). In the MAO group, adiponectin levels contributed
positively and significantly (b = 0.52; p = 0.045) with the
variability of HDL-c and explained 59% of the plasma
HDL-c variance (r2 = 0.59) (Figure 1C). In addition, adi-
ponectin was associated negatively and significantly (b =
-0.524; p = 0.028) with the variability of triglycerides
and explained 38% of the plasma triglycerides variance
(r2 = 0.38). In the LHO group, unacylated ghrelin levels
contributed positively and significantly (b = 0.630; p =
0.032) with the variability of HDL-c and explained 61%
of the plasma HDL-c variance (r2 = 0.61) (Figure 1D).
In addition, leptin was associated negatively and
Table 1 Anthropometric, body composition, hormonal and biochemical parameters of obese groups and non-obese
control subjects
Variables MHO
(n = 21)
MAO
(n = 17)
LHO
(n = 21)
Non-obese
(n = 21)
Age (yr) 37 ± 5 38 ± 11 34 ± 9 33 ± 6
Gender (Male/female) 4/17 6/11 6/15 5/16
BMI (kg/m2) 41.4 ± 4.1 43.3 ± 4.7 48.4 ± 8.3‡ 22.1 ± 2.9§,¶,**
Waist circumference (cm) 121.1 ± 13.5 129.0 ± 14.3 137.0 ± 15.4 74.8 ± 7.6§,¶,**
Systolic BP (mmHg) 124.6 ± 5.2 128.5 ± 7.5 127.4 ± 7.1 121.4 ± 5.9
Diastolic BP (mmHg) 78.2 ± 6.4 77.6 ± 9.0 76.8 ± 7.7 74.2 ± 8.9
FFM % 38.0 ± 13.1 33.5 ± 15.2 35.0 ± 14.1 nd
BFM % 43.2 ± 16.4 47.5 ± 12.4 49.8 ± 14.4 nd
REE kcal/d 1608 ± 285 1732 ± 299 1827 ± 352 nd
Glucose (mmol/L) 5.3 ± 0.3 5.4 ± 0.6 5.0 ± 0.5 4.5 ± 0.5§,¶
Insulin (mU/L) 16.0 ± 8.3 26.1 ± 10.3* 22.1 ± 7.4 7.1 ± 3.3§,¶,**
HOMA-IR score 3.8 ± 2.3 6.1 ± 2.5* 4.5 ± 1.6† 1.4 ± 0.7§,¶,**
hs-CRP (mg/L) 5.3 ± 2.2 6.5 ± 3.9 13.8 ± 4.6†,‡ 1.0 ± 0.6§,¶,**
Creatinine (μmol/L) 60.6 ± 4.2 65.5 ± 3.8 57.6 ± 5.2 53.7 ± 2.2
Adiponectin (mg/L) 7.5 ± 3.6 4.9 ± 2.9* 6.1 ± 3.4 9.8 ± 4.8¶,**
Resistin (ng/mL) 17.9 ± 7.5 17.1 ± 9.0 22.3 ± 13.2 10.9 ± 3.4§,¶,**
Leptin (ng/mL) 58.2 ± 22.3 65.3 ± 24.6 82.1 ± 48.4‡ 12.6 ± 10.3§,¶,**
Ghrelin (pg/mL) 185.3 ± 85.3 150.3 ± 61.6 161.2 ± 49 298.6 ± 99.4§,¶,**
Free fatty acids (mmol/L) 0.5 ± 0.2 0.6 ± 0.2 0.7 ± 0.2‡ 0.4 ± 0.2¶,**
Triglycerides (mmol/L) 0.9 ± 0.3 2.4 ± 0.8* 1.0 ± 0.2† 0.9 ± 0.1¶
Total cholesterol (mmol/L) 4.4 ± 0.5 4.4 ± 0.7 3.9 ± 0.7 4.3 ± 0.5
HDL-cholesterol (mmol/L) 1.36 ± 0.1 0.72 ± 0.1* 0.76 ± 0.1‡ 1.56 ± 0.1¶,**
LDL-cholesterol (mmol/L) 3.1 ± 0.5 3.3 ± 0.7 3.1 ± 0.6 2.3 ± 0.5
ApoA-I (g/L) 1.6 ± 0.2 1.28 ± 0.1* 1.2 ± 0.1‡ 1.7 ± 0.2¶,**
ApoB-100 (mg/L) 856.1 ± 165 947.7 ± 289* 771.3 ± 269† 736.9 ± 126¶
ApoC-III (mg/L) 102.1 ± 20.3 169.5 ± 71.6* 93.8 ± 15.2† 114.0 ± 30.1¶
ApoC-II (mg/L) 34.5 ± 9.5 56.5 ± 19.5* 29.4 ± 8.4† 36.8 ± 10.3¶
Total apoC-III ⁄ total apoC-II 3.1 ± 0.7 3.0 ± 0.6 3.2 ± 0.7 2.9 ± 0.6
ApoB-48 (mg/L) 4.1 ± 1.7 8.8 ± 4,0* 3.5 ± 1.7† 3.9 ± 1.8¶
Values are means ± SD. Statistical significance is from Mann-Whitney U-test.
BFM, body fat mass; BMI, body mass index; BP, blood pressure; FFM, free fat mass; LHO, low HDL-cholesterol obese; MAO, metabolically abnormal obese; MHO,
metabolically healthy obese; REE, resting energy expenditure; nd, not determined.
*p < .05 MAO vs. MHO.
† p < .05 MAO vs. LHO.
‡ p < .05 LHO vs. MHO.
§ p < .05 MHO vs. Non-obese.
¶ p < .05 MAO vs. Non-obese.
**p < .05 LHO vs. Non-obese.
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significantly (b = -0.479; p = 0.036) with the variability
of triglycerides and explained 40% of the triglycerides
variance (r2 = 0.40).
Discussion
In this study, we have shown that specific hormone pro-
files were associated with HDL-c levels in the three sub-
sets of obese patients we investigated: metabolically
healthy obese (MHO) patients, metabolically abnormal
obese (MAO) patients and isolated low-HDL-c obese
(LHO) patients. Our main results show a strong and
positive correlation between HDL-c and unacylated
ghrelin levels in the LHO group, and between HDL-c
and adiponectin levels in the MAO group, indepen-
dently of insulin resistance and hs-CRP levels in both
cases.
The first subset of our obese patients corresponded to
MHO patients described in the literature, which is
thought to represent between 20-30% of the obese
population [6]. Their lipid and apoprotein profiles were
indistinguishable from our non-obese control group.
Despite the difference in insulin resistance between
MHO and control groups, we confirmed the high insu-
lin sensitivity of this group compared to MAO and
LHO obese groups [6]. High adiponectin concentrations
have been associated with the MHO phenotype [6]. We
also documented higher serum adiponectin levels in our
MHO group compared to the MAO group, but these
two groups displayed the same hormonal profiles
regarding adipose tissue-derived leptin or resistin and
stomach derived ghrelin.
The second subset corresponded to the MAO patients,
a group that displayed the typical dyslipidaemia seen in
insulin resistant patients. This pathophysiology is widely
explained by the accumulation of triglyceride-rich lipo-
proteins (TRL) from the liver (TRL-apoB-100 or VLDL)
and from the intestine (TRL-apoB-48 or chylomicrons).
This accumulation of TRL has been attributed to the
overproduction of VLDL [3] and chylomicrons [15]
associated with a defective TRL removal due to the
reduction of lipoprotein lipase (LPL) activity mainly in
the post-prandial state [16] in a context of competition
between VLDL and chylomicrons for this common,
saturable, removal pathways, to abnormalities in the
apoprotein composition of TRL [17] and to a defect in
the hepatic uptake of TRL [16]. The increase in the
plasma resident time of the TRL would enhance choles-
terol ester transfer protein (CETP) exchange of triglycer-
ides and cholesteryl ester between HDL, and LDL on
one hand and TRL on the other hand leading to the
increase of HDL catabolism and the increase formation
of small and dense LDL [3,16]. In this study, we have
confirmed that a high level of insulin resistance is a
driving parameter in the pathophysiology of the dyslipi-
daemia seen in the MAO group compared to the MOA
and LHO groups and found the typical lipid profile:
increased plasma triglycerides, apoB-100, apoB-48,
apoC-III and apoC-II, and decreased HDL-c and apoA-
I. The same total apoC-III/apoC-II ratios between the
subgroups of obese patients suggest that this parallel
increase in apoproteins having opposite functional
effects in the TRL clearing process is most likely sec-
ondary to the increase of plasma TRL, as we have pre-
viously reported for type 2 diabetic patients [18]. In our
multiple regression analysis, adiponectin levels were
Table 2 Relationships between plasma HDL-c or
triglyceride levels and anthropometric, hormonal and
biochemical parameters in obese groups and non-obese
control subjects
Variables b SE R2 p-value
TG levels-non obese
Adiponectin -0.384 0.238 0.22 0.041
FFA 0.089 0.267 0.22 0.083
Ghrelin 0.200 0.163 0.22 0.468
TG levels-MHO
Adiponectin -0.414 0.229 0.29 0.037
HOMA score 0.247 0.167 0.29 0.116
Leptin 0.052 0.005 0.29 0.665
TG levels-MAO
Adiponectin -0.524 1.020 0.38 0.028
HOMA score 0.371 0.911 0.38 0.064
FFA 0.075 0.456 0.38 0.120
TG levels-LHO
Leptin -0.479 0.246 0.40 0.036
FFA -0.331 0.197 0.40 0.062
Resistin -0.189 0.005 0.40 0.678
HDL-c levels-non obese
Insulin -0.423 0.219 0.350 0.039
Leptin -0.130 0.159 0.350 0.090
Ghrelin -0.056 0.045 0.350 0.103
HDL-c levels-MHO
BMI -0.732 0.345 0.320 0.028
Insulin -0.120 0.102 0.320 0.097
adiponectin 0.113 0.069 0.320 0.234
HDL-c levels-MAO
Adiponectin 0.520 2.569 0.59 0.045
Ghrelin 0.390 0.234 0.59 0.148
Insulin 0.012 0.671 0.59 0.472
HDL-c levels- LHO
Ghrelin 0.630 1.478 0.61 0.032
Leptin 0.249 0.315 0.61 0.129
Insulin 0.035 0.061 0.61 0.158
Multivariate regression models for the relationships between plasma HDL-c or
triglyceride levels and age, gender, body mass index (BMI), waist, body fat
mass (BFM), fat free mass (FFM), glucose, homeostasis model assessment-
insulin resistance (HOMA-IR), hs-C-reactive protein (hs-CRP), free fatty acids
(FFA), apoA-I, apoB-100, apoB-48, apoC-II, apoC-III, apoC-III/apoC-II, insulin,
adiponectin, leptin, resistin, ghrelin for obese and non-obese groups.
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strongly and positively correlated with the HDL-c levels
and were negatively correlated with TG levels indepen-
dently of BMI, insulin resistance and hs-CRP levels. In
our study, this negative association between adiponectin
and TG levels was shared by the control and the MHO
and MAO groups but not by the LHO group. This dif-
ference could be caused by the complexity of the factors
regulating TG metabolism. Indeed, a kinetic study has
shown that adiponectin, but not leptin or resistin, was
the most significant predictor for plasma VLDL apoB
concentration, independently of both insulin resistance
and size of adipose tissue compartments in subjects
with a large range of BMI (from 22 to 35 kg/m2) but
that plasma VLDL apoB kinetic was controlled differ-
ently, with adiponectin and total body fat regulating cat-
abolism and insulin resistance regulating hepatic
secretion [19]. Adiponectin levels explained 59% of the
variance of HDL-c, thus showing a tight link between
these two parameters. A positive correlation between
plasma adiponectin and HDL-c has already been found
in several studies that have included non diabetic [20],
diabetic [21] and obese patients [22]. Moreover, two
kinetic studies have found similar results showing a
strong negative correlation between adiponectin and
apoA-I FCR (fractional catabolic rate) [22,23], although
in one study, this only occurred in the non-obese group
[22]. This negative correlation has been shown to be
independent of BMI, body fat distribution and insulin
sensitivity, which suggests that adiponectin may have a
direct role in HDL metabolism [23]. The inverse rela-
tionship shown in vivo between adiponectin and plasma
hepatic lipase activity in non diabetic and diabetic
patients could be a link between plasma adiponectin
levels and HDL metabolism [24].
The third subset of our obese patients, characterised
by isolated low-HDL-c levels (LHO) represented an
intermediate obese population between the MHO and
MAO groups. Despite a higher BMI that explained the
Figure 1 Association in stepwise regression analysis between plasma HDL-c levels and several parameters in non-obese and obese
subjects. Relationships between HDL-c levels and: plasma insulin in non-obese control subjects (A); body mass index (BMI) in metabolically
healthy obese (MHO) patients (B); serum adiponectin in metabolically abnormal obese (MAO) patients (C); serum unacylated ghrelin in isolated
low HDL-c obese (LHO) patients (D).
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significantly higher levels of serum leptin, the insulin
sensitivity of this group is in between the two other
groups. A positive association has been shown between
BMI and triglyceride concentration, which is stronger
for visceral than for subcutaneous abdominal adipose
tissue [25], but we did not assess these two parameters.
Despite higher BMI, LHO patients displayed normal tri-
glyceride levels. Their higher BMI could reflect a better
expandability of adipose tissue in the LHO group, per-
mitting a safer storage of fat and avoiding metabolic
syndrome [26]. Indeed, the lipid profile of LHO group
was comparable to that of the MHO group, with the
exception of FFA, HDL-c and apoA-I levels. We only
found a negative correlation between leptin and trigly-
ceride levels in the LHO group. Their normal triglycer-
ide concentrations could be due to a better insulin and
leptin sensitivity in this group compared to the MAO
group. Indeed, leptin has been negatively associated with
hepatic VLDL-TG secretion rate independently of
plasma FFA concentrations, possibly by stimulating
hepatic fatty acid oxidation and decreasing de novo lipo-
genesis [27]. Hs-CRP levels were significantly higher in
the LHO group compared to the two other obese
groups and could partly explain the low HDL-c levels.
Indeed, the metabolism, plasma level and apolipoprotein
contents of HDL can be strongly impaired in acute and
chronic inflammation, including obesity [28]. Neverthe-
less, multiple regression analysis showed that only
unacylated ghrelin levels were positively correlated with
HDL-c levels, which explained 61% of the variance of
HDL-c, thus demonstrating a tight link between these
two parameters. The association between plasma ghrelin
levels and insulin resistance is debated. Whereas low
levels of total plasma ghrelin have been associated with
insulin resistance [29], the same negative association has
been shown between plasma total or deacylated ghrelin
and insulin resistance but a positive association between
plasma acylated ghrelin or acylated to deacylated ghrelin
ratio and insulin resistance [13]. In the present study,
the significant association between low serum unacy-
lated ghrelin (we did not measure serum acylated ghre-
lin for technical reasons) and low HDL-c levels could be
partly explained by the same pathophysiology of the
MAO group. However, our LHO group did not display
hypertriglyceridaemia. An explanation for this could be
an increased in post-prandial response in triglyceride
levels that was not seen in our fasting measurements.
Alternatively, serum ghrelin could act more directly in
HDL metabolism by interacting with a species of HDL
associated with paraoxonase and apolipoprotein J [30],
but further studies are needed to characterize this
mechanism. Several HDL turnover studies have been
performed to elucidate the mechanism that results in
low HDL-c levels, and have included subjects with
normal TG levels, but the results are contradictory. On
the one hand, Le et al found decreased apoA-I produc-
tion rate and normal apoA-I FCR in low-HDL-c and
normal TG subjects compared to normal HDL-c and
normal TG subjects [31]. On the other hand, Brinton et
al and Gylling H et al found increased apoA-I FCR in
low-HDL-c and normal TG subjects [32,33] (as it has
been shown in these and other studies in low-HDL-c
and high TG subjects [32,34]), but no difference in
apoA-I production rate compared to normal HDL-c and
normal TG subjects [32,33]. HDL-c levels are under
considerable genetic control with heritability estimates
of up to 80% [12]. Among the genetic variants of genes
involved in HDL metabolism, a polymorphism (g.-1062
G > C) identified in the promoter region of the ghrelin
gene has been independently associated with serum
HDL-c levels in a population of type 2 diabetic Korean
patients [35]. However, another study found no associa-
tion between five SNPs in the ghrelin gene and HDL-c
levels in a Canadian population [36]. Further genetic
studies are needed.
In conclusion, this study shows that the HDL-c levels
are associated with a specific plasma hormonal profile in
different subsets of class II and III obese patients. The
low HDL-c level in the metabolically abnormal obese
(MAO) patients was mainly driven by insulin resistance
and was associated with a low level of serum adiponec-
tin. The isolated low-HDL-c obese (LHO) patients
represented a very interesting population with a level of
insulin sensitivity that was between those of the MAO
group and the metabolically healthy obese (MHO)
group. These patients also showed a high level of hs-
CRP and both of these factors could partly explain the
low HDL-c levels associated with a direct or indirect
role of serum ghrelin levels. Further studies are needed
to investigate the direct or indirect role of ghrelin and
adiponectin, and to better assess the importance of the
genetic background or hormonal profile in HDL-c meta-
bolism of obese patients.
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